GMAB - Genmab A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.22
-0.08 (-0.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close20.30
Open19.97
Bid20.05 x 800
Ask21.98 x 800
Day's Range19.79 - 20.55
52 Week Range16.24 - 25.42
Volume723,842
Avg. Volume440,552
Market Cap13.132B
Beta (5Y Monthly)0.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.60
  • PR Newswire

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    Deutsche Bank today announced that the presentations from the March 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US.

  • CNW Group

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

  • Hedge Funds Have Never Been This Bullish On Genmab A/S (GMAB)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Genmab A/S (GMAB)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • PR Newswire

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
    Benzinga

    The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Spherix Inc (NASDAQ: SPEX) (added to Friday's advance on clinching an option agreement for coronavirus treatment)Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) * ABIOMED, Inc. (NASDAQ: ABMD) * Acasti Pharma Inc (NASDAQ: ACST) * Achieve Life Sciences Inc (NASDAQ: ACHV) * Acorda Therapeutics Inc (NASDAQ: ACOR) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADMA Biologics Inc (NASDAQ: ADMA) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Akers Biosciences Inc (NASDAQ: AKER) * Akorn, Inc. (NASDAQ: AKRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * Amarin Corporation plc (NASDAQ: AMRN) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP) * Anixa Biosciences Inc (NASDAQ: ANIX) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Aptinyx Inc (NASDAQ: APTX) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Artelo Biosciences Inc (NASDAQ: ARTL) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Auris Medical Holding Ltd (NASDAQ: EARS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) * Aytu Bioscience Inc (NASDAQ: AYTU) * Bausch Health Companies Inc (NYSE: BHC) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * Bio-Path Holdings Inc (NASDAQ: BPTH) * BioCardia Inc (NASDAQ: BCDA) * BioLife Solutions Inc (NASDAQ: BLFS) * BioSig Technologies Inc (NASDAQ: BSGM) * bluebird bio Inc (NASDAQ: BLUE) * Boston Scientific Corporation (NYSE: BSX) * Elanco Animal Health Inc (NYSE: ELAN) * Glaukos Corp (NYSE: GKOS) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Celcuity Inc (NASDAQ: CELC) * CELYAD SA/ADR (NASDAQ: CYAD) * Cerecor Inc (NASDAQ: CERC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) * Edesa Biotech Inc (NASDAQ: EDSA) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Ekso Bionics Holdings Inc (NASDAQ: EKSO) * Endologix, Inc. (NASDAQ: ELGX) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Enochian Biosciences Inc (NASDAQ: ENOB) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evogene Ltd (NASDAQ: EVGN) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Geron Corporation (NASDAQ: GERN) * Glaukos Corp (NYSE: GKOS) * Gossamer Bio Inc (NASDAQ: GOSS) * Heron Therapeutics Inc (NASDAQ: HRTX) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * ImmuCell Corporation (NASDAQ: ICCC) * Incyte Corporation (NASDAQ: INCY) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Ionis Pharmaceuticals Inc (NASDAQ: IONS) * Iradimed Corp (NASDAQ: IRMD) * Jaguar Health Inc (NASDAQ: JAGX) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * KemPharm Inc (NASDAQ: KMPH) * KITOV PHARMA LT/S ADR (NASDAQ: KTOV) * Kura Oncology Inc (NASDAQ: KURA) * Lantheus Holdings Inc (NASDAQ: LNTH) * MacroGenics Inc (NASDAQ: MGNX) * Medigus ADR (NASDAQ: MDGS) * Mediwound Ltd (NASDAQ: MDWD) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Mylan NV (NASDAQ: MYL) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * Neuronetics Inc (NASDAQ: STIM) * Obalon Therapeutics Inc (NASDAQ: OBLN) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Orthofix Medical Inc (NASDAQ: OFIX) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Passage Bio Inc (NASDAQ: PASG) * PDS Biotechnology Corp (NASDAQ: PDSB) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) * Pluristem Therapeutics Inc. (NASDAQ: PSTI) * Plus Therapeutics Inc (NASDAQ: PSTV) * Polarityte Inc (NASDAQ: PTE) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * PPD Inc (NASDAQ: PPD) * Precigen Inc (NASDAQ: PGEN) * Predictive Oncology Inc (NASDAQ: POAI) * Radius Health Inc (NASDAQ: RDUS) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Spero Therapeutics Inc (NASDAQ: SPRO) * Stemline Therapeutics Inc (NASDAQ: STML) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) * SurModics, Inc. (NASDAQ: SRDX) * Synlogic Inc (NASDAQ: SYBX) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tenax Therapeutics Inc (NASDAQ: TENX) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * TherapeuticsMD Inc (NASDAQ: TXMD) * Titan Medical Inc. (NASDAQ: TMDI) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Translate Bio Inc (NASDAQ: TBIO) * Unity Biotechnology Inc (NASDAQ: UBX) * Unum Therapeutics Inc (NASDAQ: UMRX) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Vericel Corp (NASDAQ: VCEL) * Viking Therapeutics Inc (NASDAQ: VKTX) * VIVUS, Inc. (NASDAQ: VVUS) * Voyager Therapeutics Inc (NASDAQ: VYGR) * Xenetic Biosciences Inc (NASDAQ: XBIO) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) * Zimmer Biomet Holdings Inc (NYSE: ZBH)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Mesoblast Plans To Evaluate Stem Cell Therapy Candidate For Coronavirus Respiratory Distress Mesoblast limited (NASDAQ: MESO) said it plans to evaluate its allogenic mesenchymal stem cell product candidate remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19 in the U.S., Australia, China and Europe.The company said it is in active discussions with various government and regulatory authorities, medical institutions and pharma companies.In premarket trading Tuesday, the shares were surging 28.35% to $7.90.Emergent Biosolutions To Provide Manufacturing Support For Novavax's COVID-19 Program Emergent Biosolutions Inc (NYSE: EBS) said it has entered into an agreement with Novavax, Inc. (NASDAQ: NVAX), under which the former will use its molecule-to-market contract development and manufacturing service to support bringing into the latter's vaccine candidate to protect against COVID-19 into the clinic. Emergent will produce the COVID-19 experimental vaccine candidate developed using Novavax's proprietary recombinant protein nanoparticle technology platform. Emergent said it has initiated work and anticipates commencement of a Phase 1 study within the next four months.Separately, Novavax said the Coalition for Epidemic Preparedness awarded it an initial funding of $4 million to support its COVID-19 vaccine program.In premarket trading Tuesday, Emergent shares were adding 0.95% to $53.02 and Novavax shares were surging up 24.35% to $12.46.Genmab Appoints Anthony Mancini As Chief Operating Officer GENMAB A/S/S ADR (NASDAQ: GMAB) announced the appointment of Anthony Mancini as EVP and COO effective March 23. Mancini's role calls for him to oversee the company's commercial, corporate development, business development and information technology functions.Glaukos Set To Join S&P SmallCap 600 Index Ophthalmic medtech and pharma company Glaukos is set to join the S&P SmallCap 600 Index, effective prior to the open of trading March 13, replacing AK Steel Holding Corporation (NYSE: AKS), which has agreed to be acquired by Cleveland-Cliffs Inc (NYSE: CLF).Glaukos shares were trading 7.5% higher at $38.49 in the premarket session. MediciNova Plans Clinical Study Of Ibudilast In Pneumonia, Acute Respiratory Distress Syndrome MediciNova, Inc. (NASDAQ: MNOV) said it plans to initiate the development of MN-166 for severe pneumonia and acute respiratory distress syndrome following positive results in a recent preclinical study in an animal model. The animal study showed treatment with the investigational candidate reversed histological changes, including inflammation, hemorrhage, alveolar congestion and alveolar edema.Rockwell Medical Faces Pressure From Activist Investor Medical Resources Acquisition said on Feb. 25 it offered Rockwell Medical Inc (NASDAQ: RMTI) $15 million in equity investment for three board seats currently held by John Cooper, Mark Ravich and Lisa Colleran.The investment firm said Rockwell's board has failed to provide appropriate governance, resulting in reckless spending, a cash deficiency and a lack of operational controls that have impacted stock performance.View more earnings on IBBRockwell acknowledged receiving an email from Medical Resources Acquisition in a press release."The Board of Directors is in the process of reviewing the materials submitted by MRAG. Stockholders do not need to take any action at this time," the company said. The stock was trading 9.37% higher at $3.50 in Tuesday's premarket session. Acceleron Discontinues Midstage Neurological Disorder Drug Study Acceleron Pharma Inc (NASDAQ: XLRN) said treatment with ACE-083 in patients with Charcot-Marie-Tooth disease did not demonstrate functional improvement in a Phase 2 trial.The company said it is discontinuing the development of ACE-083.Earnings Organogenesis Holdings Inc's (NASDAQ: ORGO) fourth-quarter revenues climbed 17% to $74.6 million. The net loss per share narrowed from 12 cents to 4 cents. For 2020, the company guided to revenues of $273 million to $277 million. The results as well as the guidance were above consensus.The stock jumped 14.56% to $3.54 in after-hours trading.Aduro BioTech Inc (NASDAQ: ADRO) said its fourth-quarter revenues increased from $2.8 million in 2018 to $3.6 million in 2019. The loss per share narrowed from 33 cents to 24 cents, while analysts expected a narrower loss of 21 cents per share.The stock slipped 4.89% to $2.92 in after-hours trading.Assertio Therapeutics Inc (NASDAQ: ASRT) reported fourth-quarter revenues of $59.23 million and a loss of $2.65 per share. In the year-ago quarter, the company reported revenues of $42.6 million and a loss of 38 cents per share. On a non-GAAP basis, the company reported a loss of 14 cents per share for the recent quarter compared to expectations for a profit of 14 cents per share.The stock fell 11.21% to 95 cents in after-hours trading.On The Radar PDUFA Dates The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE: BMY) sBLA for Opdivo \+ Yervoy as treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar.Earnings * Precision BioSciences Inc (NASDAQ: DTIL) (before the market open) * Akebia Therapeutics Inc (NASDAQ: AKBA) (before the market open) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (before the market open) * InspireMD Inc (NYSE: NSPR) (before the market open) * ChemoCentryx Inc (NASDAQ: CCXI) (after the close) * CV Sciences Inc (OTC: CVSI) (after the close) * Fulgent Genetics Inc (NASDAQ: FLGT) (after the close) * Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) (after the close) * RA Medical Systems Inc (NYSE: RMED) (after the close) * Protagonist Therapeutics Inc (NASDAQ: PTGX) (after the close) * Castle Biosciences Inc (NASDAQ: CSTL) (after the close) * Constellation Pharmaceuticals Inc (NASDAQ: CNST) (after the close)Related Link: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues See more from Benzinga * The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study * The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • CNW Group

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

  • Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?
    Simply Wall St.

    Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

    Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...

  • If You Had Bought Genmab (CPH:GMAB) Stock Five Years Ago, You Could Pocket A 252% Gain Today
    Simply Wall St.

    If You Had Bought Genmab (CPH:GMAB) Stock Five Years Ago, You Could Pocket A 252% Gain Today

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

  • CNW Group

    ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands , Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced that its wholly owned subsidiary U-Protein Express BV signed a long-term lease contract for the new multi-tenant building for life sciences "Accelerator" at the Utrecht Science Park ( Utrecht, The Netherlands ). In addition to accommodating large biotechnology companies, the new building will offer space to companies that want to accelerate their development.

  • GlobeNewswire

    Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

    Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional.

  • Is Genmab A/S's (CPH:GMAB) 12% ROE Strong Compared To Its Industry?
    Simply Wall St.

    Is Genmab A/S's (CPH:GMAB) 12% ROE Strong Compared To Its Industry?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • What Did Genmab A/S's (CPH:GMAB) CEO Take Home Last Year?
    Simply Wall St.

    What Did Genmab A/S's (CPH:GMAB) CEO Take Home Last Year?

    In 2010 Jan G. van de Winkel was appointed CEO of Genmab A/S (CPH:GMAB). This analysis aims first to contrast CEO...

  • Don't Sell Genmab A/S (CPH:GMAB) Before You Read This
    Simply Wall St.

    Don't Sell Genmab A/S (CPH:GMAB) Before You Read This

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • Benzinga

    Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates

    FDA activity remained brisk in August. The FDA gave its nod for a majority of drugs that came up for review, although Vanda Pharmaceuticals Inc. (NASDAQ: VNDA )'s jet lag disorder drug Hetlioz and Sarepta ...

  • Benzinga

    The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...

  • Benzinga

    IPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of China

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Douyu International Holdings Ltd (DOYU) will issue nearly 67.4 million ...

  • Genmab IPO raises $582m, becoming second largest US IPO ever by a bio-tech company
    Yahoo Finance Video

    Genmab IPO raises $582m, becoming second largest US IPO ever by a bio-tech company

    International bio-tech company Genmab is on a mission to improve the life of cancer patients, after becoming the second largest U.S. IPO ever by a bio-tech company. Genmab CEO Jan van de Winkel joins Yahoo Finance's Adam Shapiro and Julie Hyman to discuss.